Systemic sclerosis (scleroderma) trials in Spain
17 of 21 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Taking peopleA Study of AZD0120 in Autoimmune Diseases
- Where
- Barcelona, Madrid
- Age
- 18 years to 75 years
- People
- 27 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07295847 - Phase 3Taking peopleRollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
- Where
- A Coruña, Barcelona, Castellon, Granada, Las Palmas de Gran Canaria, Madrid, Valencia, Valladolid, Vigo
- Age
- 5 years to 80 years
- People
- 1,072 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07691970 - Phase 3Not yet taking people in SpainRollover Study for Participants Who Have Completed a Previous Clinical Study with Anifrolumab (Saphnelo) and Clinically Benefited from Continued Treatment.
- Where
- A Coruña, Barcelona, Castello De La Plana, Granada, Las Palmas De Gran Canaria, Madrid, Valencia, Vigo. Pontevedra
- People
- 340 worldwide
- Run by
- AstraZeneca AB
See details and how to join2026-526419-13-00 · EU 2026-526419-13-00 - Phase 1Taking peopleA Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- Where
- Córdoba, Pamplona, Seville, Valencia
- Age
- 18 years to 70 years
- People
- 80 worldwide
- Run by
- CRISPR Therapeutics
See details and how to joinNCT06925542 - Phase 1/2Taking peopleControlling Hyperactive Immunity With Long-lived Lymphocytes
- Where
- Madrid
- Age
- 18 years and over
- People
- 16 worldwide
- Run by
- Quell Therapeutics Limited
See details and how to joinNCT07473154 - Phase 1/2Taking peopleStudy QEL-005-CLN-01. Phase I/II study of QEL-005 in patients with diffuse cutaneous systemic sclerosis (dcSSc) and in patients with difficult to treat rheumatoid arthritis (D2TRA).
- Where
- Madrid
- Age
- 18 years and over
- People
- 8 worldwide
- Run by
- Quell Therapeutics Limited
See details and how to join2025-523971-46-00 · EU 2025-523971-46-00 - Phase 2Taking peopleEvaluation of MTX-474 in Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)
- Where
- Barcelona, Córdoba, Málaga, Valencia
- Age
- 18 years and over
- People
- 36 worldwide
- Run by
- Mediar Therapeutics Inc.
See details and how to join2025-523288-39-00 · EU 2025-523288-39-00 - Phase 3Taking peopleA Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
- Where
- Badalona, Barakaldo, Barcelona, Huelva, L'hospitalet De Llobregat, Madrid, Sabadell, Valencia
- Age
- 18 years and over
- People
- 448 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07497087 · EU 2025-523884-39-00 - Phase 2Taking peopleEncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
- Where
- Barcelona, Córdoba, Málaga, Valencia
- Age
- 18 years and over
- People
- 85 worldwide
- Run by
- Mediar Therapeutics
See details and how to joinNCT07287670 - Phase 3Not yet taking people in SpainA Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
- Where
- A Coruña, Barcelona, L'hospitalet De Llobregat, Málaga
- Age
- 16 years and over
- People
- 92 worldwide
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT07335562 · EU 2025-524337-11-00 - Phase 3Taking peopleA Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
- Where
- Barcelona, Bilbao, VigoPontevedra
- Age
- 18 years and over
- People
- 514 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT06716606 - Phase 2/3Taking peopleA Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- Where
- Barcelona, Bilbao, Granada, Madrid, Pamplona, Sabadell, Sevilla, Valencia, Valladolid, Vigo
- Age
- 18 years and over
- People
- 300 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT05878717 · EU 2023-503219-14-01 - Phase 2Taking peoplePlatform Clinical Study for Conquering Scleroderma
- Where
- Barcelona, Córdoba, Madrid, Sabadell, Valencia
- Age
- 18 years and over
- People
- 400 worldwide
- Run by
- Scleroderma Research Foundation, Inc.
See details and how to joinNCT06195072 · EU 2023-507129-40-00 - Phase 1Taking peopleA Phase 1 Study of the Safety and Preliminary Efficacy of CTX112 in Adult Subjects With Refractory Autoimmune Disease.
- Where
- Córdoba, Pamplona, Sevilla, Valencia
- Age
- 18 years and over
- People
- 51 worldwide
- Run by
- CRISPR Therapeutics AG
See details and how to join2024-518528-54-00 · EU 2024-518528-54-00 - Phase 2Taking peopleAlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Where
- Sevilla
- Age
- 18 years and over
- People
- 90 worldwide
- Run by
- Artiva Biotherapeutics, Inc.
See details and how to joinNCT06991114 · EU 2025-520461-41-00 - Phase 1Taking peopleA Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
- Where
- Barcelona, Madrid
- Age
- 18 years and over
- People
- 125 worldwide
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT07115745 · EU 2024-517681-41-00 - Phase 2Taking peopleA Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
- Where
- A Coruña, Barcelona, Bilbao, Córdoba, Málaga, Sabadell, Valencia
- Age
- 18 years and over
- People
- 162 worldwide
- Run by
- Galderma R&D
See details and how to joinNCT07047690 · EU 2025-522294-11-00